Neonatal diabetes mellitus (NDM), defined as persistent hyperglycemia occurring in the first months of life, is a rare cause of hyperglycemia and is often misdiagnosed as type 1 diabetes mellitus (T1DM). Numerous reports have shown that the successful transition from insulin to sulfonylurea agents can be achieved in up to 90% of patients with NDM. However, most of the reports pertain to infants; the literature is limited regarding treatment of adults with NDM. We present our experience with a patient with permanent NDM, initially misdiagnosed as T1DM, who subsequently was successfully transitioned to oral sulfonylurea therapy after 37 years of insulin dependence.
INTRODUCTION
Neonatal diabetes mellitus (NDM), defined as persistent hyperglycemia occurring in the first six months of life, is a rare cause of hyperglycemia with an estimated incidence of 1 in 100,000 to 1 in 260,000 live births [1] [2] [3] . Almost all cases of NDM have monogenic etiology in contrast to the autoimmune diabetes presenting in children beyond 6 months of age [4] . There are 22 known genetic causes of NDM (mutations in 21 genes and methylation abnormalities at the 6q24 locus) that identify different clinical subtypes of the disease [1] . This includes transient NDM (TNDM), permanent NDM (PNDM), and complex syndromes in which NDM is often the presenting feature (i.e., Wolcott-Rallison syndrome) [1] . The most common cause of NDM are mutations in the adenosine triphosphate (ATP)-sensitive potassium channel (K-ATP channel) subunit genes ABCC8 and KCNJ11 which regulate the release Enhanced content To view enhanced content for this article go to http://www.medengine.com/Redeem/22C4 F0602852B901.
of insulin from pancreatic b cells [1, [5] [6] [7] [8] . The pancreatic b-cell K-ATP channels are hetero-octamers assembled by four Kir6.2 subunits and four high-affinity sulfonylurea receptor 1 (SUR1) subunits encoded by the genes KCNJ11and ABCC8, respectively [9] [10] [11] .
KCNJ11 mutations are more frequent in patients with PNDM, whereas mutations in ABCC8 cause TNDM more frequently [8] . The majority of infants with NDM are small for gestational age, which may be related to decreased insulin secretion in the fetus and exhibit postnatal catch-up growth with insulin therapy [12] . The most severe defect includes marked developmental delay and early onset epilepsy, also known as DEND syndrome [8, 10] .
Subcutaneous insulin was routinely used in the past to treat patients with this disorder; however, studies have shown that the successful transition from insulin to sulfonylurea (SU) agents can be achieved in up to 90% of patients with NDM [11] . We report a case of PNDM whose treatment was successfully transitioned from insulin to oral SU therapy after 37 years of insulin dependence.
CLINICAL CASE
A Insulin detemir and insulin lispro were slowly decreased as the dose of SU therapy was increased. In an attempt to increase the patient's own endogenous insulin production and achieve further insulin independence, a 7-day trial of sitagliptin 100 mg QD was initiated with a subsequent increase in C-peptide to 0.9 ng/dL (BG 252 mg/dL). However, glycemic control did not improve so the sitagliptin was discontinued and a trial of dapagliflozin 5 mg QD was initiated (despite his CKD stage 3). Glycemic control significantly improved, and after dapagliflozin was increased to 10 mg QD, insulin therapy was completely discontinued (his original total daily dose of insulin was 64 units Informed consent was obtained from the patient for publication of this case report. Heterozygous activating mutations in the KCNJ11 or ABCC8 gene, which encodes the Kir6.2 subunits and SUR1 regulatory subunits of the K-ATP channel, respectively, have been implicated and account for 30% to 58% of cases of PNDM diagnosed in patients less than 6 months of age [6, 11] . Mutations in the K-ATP channels lead to decreased sensitivity to ATP inhibition; consequently, the channels remain open in the presence of glucose, thereby reducing insulin secretion [11] . SUs close K-ATP channels by an ATP-independent route thereby causing insulin secretion. Studies have
shown that many patients with diabetes caused by KCNJ11 or ABCC8 mutations can successfully switch from treatment with insulin to oral SU therapy [11] . The dose of SU therapy that is required to manage glycemia in patients with NDM, particularly to achieve insulin independence, is often higher than the maximum recommended dose for the treatment of type 2 diabetes mellitus [11] , typically needing around 0.5 mg/kg/day of glibenclamide [11, 16] . In our case, glimepiride was chosen instead of glibenclamide (glyburide) because of the ever-evolving literature reporting a lower risk of hypoglycemia [17] and lower risk of all-cause and cardiovascular-related mortality with the other readily available SUs compared to glibenclamide [18, 19] .
A report by Thurber et al. [20] found that, in patients with NDM, earlier age at initiation of SU treatment was associated with an improved response to SU therapy. This led the authors to appropriately hypothesize that perhaps the declining sensitivity to SU therapy observed with more advanced age may be due to the loss of b-cell mass over time in those treated with insulin therapy, thereby highlighting the importance of early recognition and initiation of SU therapy.
In our patient, we were able to demonstrate a rise in C-peptide as the SU dosage was increased. While it is certainly possible that Table 1 . While the lack of genetic testing is a significant limitation of our report, this To the best of our knowledge, we are the first to report the effective and safe use of SGLT2 inhibitors in a patient with NDM. While the HbA1c did not appear to improve significantly after the addition of dapagliflozin, the therapy did help to lower postprandial glycemic excursions, not adequately addressed by the SU therapy, and helped to reduce the frequency at which the patient took a correction dose of bolus insulin, or a dose of bolus insulin to assist with glycemic control when he consumed higher carbohydrate containing meals.
CONCLUSIONS
We report the case of a patient with long-standing poorly controlled NDM initially misdiagnosed and treated as having T1DM. Many patients with NDM treated with insulin-only therapy behave as brittle diabetics, with difficult to control glycemia leading to complications. The addition or transition to SU therapy may help some of these patients achieve better glycemic control, while requiring less dependence on insulin therapy. Our case highlights the importance of history taking in the management of patients with diabetes, especially the need to conduct a thorough family history, as recognition of NDM can profoundly impact the diabetes-related management of both the patient and their family members.
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